Why is rapid-acting insulin preferred for correcting hyperglycemia?

Why is rapid-acting insulin preferred for correcting hyperglycemia?

• A. It doesn’t require monitoring
• B. Rapid onset and shorter duration allow tighter postprandial control with fewer hypoglycemia risks
• C. Long duration prevents rebound hypoglycemia
• D. It is cheaper

Answer: (B)

The key idea is matching the insulin’s action to the glucose rise after a meal. Rapid-acting insulin begins working quickly after injection, reaches its peak within about one to two hours, and then wears off within a few hours. This short, fast-acting profile makes it ideal for correcting hyperglycemia because it can counteract a meal-related glucose spike promptly and then stop acting, reducing the chance of lingering effects that could cause late hypoglycemia if the meal were smaller than expected or if activity levels changed. Using a rapid-acting insulin allows tighter postprandial control, since you can correct high levels as soon as they appear and avoid prolonged insulin exposure that would extend beyond the peak glucose rise. In contrast, insulins with slower onset or longer duration don’t align as well with the meal-driven glucose increase and carry a higher risk of hypoglycemia if the dose overshoots or if meals are skipped or delayed. Other statements don’t fit because the choice isn’t about cost or avoiding monitoring; all insulin regimens require monitoring. A long-duration insulin won’t correct fast hyperglycemia as quickly and can increase the risk of late hypoglycemia due to its extended action.

The key idea is matching the insulin’s action to the glucose rise after a meal. Rapid-acting insulin begins working quickly after injection, reaches its peak within about one to two hours, and then wears off within a few hours. This short, fast-acting profile makes it ideal for correcting hyperglycemia because it can counteract a meal-related glucose spike promptly and then stop acting, reducing the chance of lingering effects that could cause late hypoglycemia if the meal were smaller than expected or if activity levels changed.

Using a rapid-acting insulin allows tighter postprandial control, since you can correct high levels as soon as they appear and avoid prolonged insulin exposure that would extend beyond the peak glucose rise. In contrast, insulins with slower onset or longer duration don’t align as well with the meal-driven glucose increase and carry a higher risk of hypoglycemia if the dose overshoots or if meals are skipped or delayed.

Other statements don’t fit because the choice isn’t about cost or avoiding monitoring; all insulin regimens require monitoring. A long-duration insulin won’t correct fast hyperglycemia as quickly and can increase the risk of late hypoglycemia due to its extended action.